These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2231940)

  • 1. Management of children with myelodysplasia: urological alternatives.
    Klose AG; Sackett CK; Mesrobian HG
    J Urol; 1990 Dec; 144(6):1446-9. PubMed ID: 2231940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prophylactic value of clean intermittent catheterization and anticholinergic medication in newborns and infants with myelodysplasia at risk of developing urinary tract deterioration.
    Kasabian NG; Bauer SB; Dyro FM; Colodny AH; Mandell J; Retik AB
    Am J Dis Child; 1992 Jul; 146(7):840-3. PubMed ID: 1496955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relevance of urethral resistance in children with myelodysplasia: its impact on upper urinary tract deterioration and the outcome of conservative management.
    Tanaka H; Kakizaki H; Kobayashi S; Shibata T; Ameda K; Koyanagi T
    J Urol; 1999 Mar; 161(3):929-32. PubMed ID: 10022727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preservation of renal function in children with myelomeningocele managed with basic newborn evaluation and close followup.
    Hopps CV; Kropp KA
    J Urol; 2003 Jan; 169(1):305-8. PubMed ID: 12478177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vesicoureteral reflux in children with myelodysplasia: natural history and results of treatment.
    Sidi AA; Peng W; Gonzalez R
    J Urol; 1986 Jul; 136(1 Pt 2):329-31. PubMed ID: 3723683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome analysis of vesicoureteral reflux in children with myelodysplasia.
    Agarwal SK; Khoury AE; Abramson RP; Churchill BM; Argiropoulos G; McLorie GA
    J Urol; 1997 Mar; 157(3):980-2. PubMed ID: 9072629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of myelomeningocele.
    Kaplan WE
    Urol Clin North Am; 1985 Feb; 12(1):93-101. PubMed ID: 3883627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postpubertal urodynamic and upper urinary tract changes in children with conservatively treated myelomeningocele.
    Almodhen F; Capolicchio JP; Jednak R; El Sherbiny M
    J Urol; 2007 Oct; 178(4 Pt 1):1479-82. PubMed ID: 17706702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clean, intermittent catheterization of infants with neurogenic bladder.
    Joseph DB; Bauer SB; Colodny AH; Mandell J; Retik AB
    Pediatrics; 1989 Jul; 84(1):78-82. PubMed ID: 2740179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonsurgical management of threatened upper urinary tracts and incontinence in children with myelomeningocele.
    Hernandez RD; Hurwitz RS; Foote JE; Zimmern PE; Leach GE
    J Urol; 1994 Nov; 152(5 Pt 1):1582-5. PubMed ID: 7933209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An objective score to predict upper tract deterioration in myelodysplasia.
    Galloway NT; Mekras JA; Helms M; Webster GD
    J Urol; 1991 Mar; 145(3):535-7. PubMed ID: 1997704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long-term urological response of neonates with myelodysplasia treated proactively with intermittent catheterization and anticholinergic therapy.
    Edelstein RA; Bauer SB; Kelly MD; Darbey MM; Peters CA; Atala A; Mandell J; Colodny AH; Retik AB
    J Urol; 1995 Oct; 154(4):1500-4. PubMed ID: 7658577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clean intermittent catheterization in the management of the neurogenic bladder in children.
    Cass AS; Luxenberg M; Gleich P; Johnson CF; Hagen S
    J Urol; 1984 Sep; 132(3):526-8. PubMed ID: 6471189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upper urinary tract deterioration in patients with myelodysplasia and detrusor hypertonia: a followup study.
    McGuire EJ; Woodside JR; Borden TA
    J Urol; 1983 Apr; 129(4):823-6. PubMed ID: 6842712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urodynamic dysfunction in walking myelodysplastic children.
    Dator DP; Hatchett L; Dyro FM; Shefner JM; Bauer SB
    J Urol; 1992 Aug; 148(2 Pt 1):362-5. PubMed ID: 1635136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of risk factors for upper urinary tract deterioration in patients with myelodysplasia.
    Seki N; Akazawa K; Senoh K; Kubo S; Tsunoda T; Kimoto Y; Naito S
    BJU Int; 1999 Oct; 84(6):679-82. PubMed ID: 10510115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endoscopic treatment of vesicoureteral reflux in patients with myelodysplasia.
    Yokoyama O; Ishiura Y; Seto C; Uchibayashi T; Ohkawa M
    J Urol; 1996 Jun; 155(6):1882-6. PubMed ID: 8618279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The urodynamic profile of myelodysplasia in childhood with spinal closure during gestation.
    Holzbeierlein J; Pope JC IV; Adams MC; Bruner J; Tulipan N; Brock JW
    J Urol; 2000 Oct; 164(4):1336-9. PubMed ID: 10992409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An alternative approach to myelodysplasia management: aggressive observation and prompt intervention.
    Teichman JM; Scherz HC; Kim KD; Cho DH; Packer MG; Kaplan GW
    J Urol; 1994 Aug; 152(2 Pt 2):807-11. PubMed ID: 8022020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Early Oxybutynin Treatment on Posterior Urethral Valve Outcomes in Infants: A Randomized Controlled Trial.
    Abdelhalim A; El-Hefnawy AS; Dawaba ME; Bazeed MA; Hafez AT
    J Urol; 2020 Apr; 203(4):826-831. PubMed ID: 31821098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.